For research use only
| Cat No. | ABC-TC0553 |
| Product Type | Human Leukemia Cell Lines |
| Cell Type | Lymphocyte-like |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Acute Myeloid Leukemia |
| Product Code | KY-821 |
KY821 is a human acute myelomonocytic leukemia cell line from peripheral blood with lymphocyte-like morphology and suspension culture properties, ideal for research use.
KY821 is a human acute myelomonocytic leukemia cell line derived from the peripheral blood of a 28-year-old male patient. The cells exhibit lymphocyte-like morphology and grow in suspension culture, representing typical KY821 cell characteristics, and may grow slowly during the initial recovery period after thawing, which should be considered in KY821 cultivation techniques. KY821 cells are characterized by granulocytic maturation and the presence of numerous double minute chromosomes (dmin) derived from chromosome 8, with amplification of the 8q22–24 region containing the MYC oncogene. In addition, KY821 harbors concurrent oncogenic NRAS and TP53 R175H/− mutations, defining key KY821 genetic traits, and sustained expression of mutant p53 is required for maintenance of the leukemic phenotype. These molecular and cytogenetic features contribute to altered stress responses and therapeutic tolerance, making KY821 and its clonal derivatives a relevant model for investigating disease resistance mechanisms in KY821, particularly those associated with dmin-driven MYC amplification and p53 dysfunction.
| Product Code | KY-821 |
| Species | Human |
| Cat.No | ABC-TC0553 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocyte-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Acute Myeloid Leukemia |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Leukemia Cell Lines |
The KY821 cell line is used in AML pathogenisis research, drug screening and resistance studies. These studies are closely associated with its unique genetic and functional characteristics, including aberrant signaling pathways, mutations in key oncogenes, and dysregulated apoptosis mechanisms. In the durg preclinical screening, the KY821 show different responses and effects to each drug due to its multiple hematopoietic growth factors. Thus KY821 would be an ideal model for drug comparative studies, enable the identification of more precise resistant clone.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
The percentage of HMB-45 expression in KY821 Cell Line was detected by flow cytometry to be approximately 71.9%.
